Valion Bio, Inc. — Form SCHEDULE 13D/A
Filed August 11, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▲ Likely positive
significance 89/100
What the filing says
3i LP commits up to $9,000,000 in investment ($3M at closing, $6M over two months) under existing Series B/C terms, conditional on due diligence and Nasdaq listing maintenance. Concurrent governance changes: CEO Michael Handley terminated immediately; Chair Sheryle Bolton steps down and becomes Special Advisor; Maier Tarlow becomes Chairman; 3i nominates two additional directors. Investment and governance changes subject to definitive documentation execution.
Why this rating
9M investment is 225% of company's 4M market value—massive dilution cushion and survival capital. CEO removal and board control shift represent transformational governance restructuring for micro-cap.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.